Discover the best sectors for growth stocks in the next decade. Explore which sectors may present an opportunity to bolster ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ:BIOA) pursuant and/or traceable to BioAge's registration statement for the initial public ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

Eli Lilly ( LLY 0.69%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Scams involving celebrities or other famous people aren't really new - and are simply a modern take on the "Spanish Prisoner" or "Nigerian Prince" schemes ...

Sales of Lilly's top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of ...